

VITROLIFE GROUP™

Conference call full year report 2024

Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the fourth quarter and full year report 2024. The presentation will be held in English.

Time: Thursday 30 January, 2025 at 10.00 a.m. CET.

To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: [Privacy policy | Vitrolife Group](#)

[Register for the call here](#)

Vitrolife Group participants:
Bronwyn Brophy O'Connor, CEO
Helena Wennerström, acting CFO

The press release for the full year report will be released at 8.00 CET on the same day.

Before the conference call, presentation material will be available at the company web page.

A recorded version of the telephone conference will be available for seven days on number +44 (0) 20 3451 9993 (International), access code 2171635#.

Gothenburg, 16 January 2025
VITROLIFE AB (publ)

Contact:
Amelie Wilson, Investor Relations, awilson@vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.